BOTHELL, Wash., April 5 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. , a developer of bioactive peptides, today announced that a review article titled “Antimicrobial peptides: therapeutic potential” was published in the April 2006 edition of Expert Opinion on Pharmacotherapy, a unique source of peer-reviewed drug evaluations and reviews. The article discusses initiatives underway to develop peptide-based therapeutics as well as the wide range of clinical applications that companies are pursuing. Authors of the review article were Helix BioMedix’s Principal Scientist Dr. Lijuan Zhang and Chief Scientific Officer Dr. Timothy J. Falla.
“There are certain attributes of antimicrobial peptides, including broad-spectrum cidal activity, novel mechanism of action and ease of synthesis, that make them excellent candidates for development as anti-infective therapeutics,” commented Timothy J. Falla. “As the fundamental issues of stability, toxicity and cost are addressed and a wider range of clinical indications emerge, there has been a resurgence of interest in peptide-based therapeutics, particularly in the areas of infection, dermatology, cancer and inflammation. At Helix BioMedix, we are currently in preclinical testing with a number of peptides targeted at wound management and have also recently developed a series of hexapeptides for dermatological indications. With the recent advancements being made, we believe that the peptides of today have a much greater chance of achieving clinical success.”
The review article in the April 2006 edition of Expert Opinion on Pharmacotherapy can be found on-line at article: http://www.expertopin.com/doi/abs/10.1517/14656566.7.6.653 .
Expert Opinion on Pharmacotherapy is a unique source of peer-reviewed drug evaluations and reviews and is internationally recognized as a leader in competitor intelligence to the pharmaceutical industry. Published by Informa Healthcare, it provides comprehensive coverage of the emerging literature on and experience with newly approved compounds and an evaluated assessment of the likely impact of these new agents on existing pharmacotherapy of specific diseases. Expert Opinion on Pharmacotherapy focuses on new drugs and drug classes from development Phase III to those that have been available to pharmacopoeia for up to 5 years.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, including over 100,000 unique peptide sequences. The company’s mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing applications. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company’s website at www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to our potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company’s ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
Contact: Helix BioMedix, Inc. David H. Kirske, 425-402-8400 dkirske@helixbiomedix.com or: Investor Relations: Cameron Associates Alison Ziegler, 212-554-5469 alison@cameronassoc.com
Helix BioMedix, Inc.
CONTACT: David H. Kirske of Helix BioMedix, Inc., +1-425-402-8400, ordkirske@helixbiomedix.com; or investors, Alison Ziegler of CameronAssociates, +1-212-554-5469, or alison@cameronassoc.com, for HelixBioMedix, Inc.
Web site: http://www.helixbiomedix.com/
